Skip to content

Immunocore

US · IMCR #2968 by market cap Listed 2021
26.41 -0.22 -0.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:10

Price chart

Pre-market 26.99 +1.35%
After-hours 26.41 0.00%
Overnight 26.20 -1.61%
37.5726.4126.412026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IMCR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -29.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 15.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 98.7% Better than 99%
Operating margin -11.3% Better than 14%
Net margin -8.9% Better than 16%
Return on equity -9.6% Better than 20%
Return on invested capital -4.8% Better than 22%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -28.4% Better than 19%
6-month return -8.4% Better than 42%
12-month return (ex latest month) -18.4% Better than 16%
Distance below 52-week high 35.1% Better than 34%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.0x Better than 81%
Debt to assets 40.9% Better than 26%
Interest coverage -0.6x Better than 23%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 60.0% Better than 36%
Upside to average target 115.1% Better than 86%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.79%
1M -18.99%
3M -27.21%
6M -10.60%
YTD -23.91%
1Y -32.30%
3Y -41.96%
5Y -30.68%

Key statistics

Price & volume

Prev close
26.63
Open
26.37
Day range
25.61 - 26.82
Avg price
26.36
Volume
546.18K
Turnover
14.40M
Amplitude
4.53%
52-week range
25.61 - 40.71

Valuation

P/E
-37.20
P/E (TTM)
-41.27
P/B
3.25
EPS
-0.71
Net profit
-36.69M
Net assets
419.70M

Share structure

Market cap
1.36B
Float cap
1.21B
Shares out
51.68M
Float shares
45.99M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-02-05
52-week range 5% of range
25.61 40.71

35.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-20.20M net over the window

Short interest

Shares short
7.79M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Immunocore (IMCR)?

Immunocore last traded at 26.41. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Immunocore's market cap?

About 1.36B.

What is the P/E ratio of Immunocore?

The trailing twelve-month P/E is -41.27. The Valuation tab shows it against the stock's own five-year range.

Does Immunocore pay a dividend?

Immunocore does not currently pay a regular dividend.

Is Immunocore a buy according to analysts?

The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 56.80, which implies 115.1% upside from the current price. This is not investment advice.

What is Immunocore's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Immunocore a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.

Immunocore discussion 0 comments

Add a comment